{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:20:08Z","timestamp":1792624808658,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007816","name":"Alcon Laboratories Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ogla.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T03:02:22Z","timestamp":1738983742000},"page":"302-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness Analysis of Hydrus Microstent for Patients with Mild to Moderate Primary Open-Angle Glaucoma in Canada"],"prefix":"10.1016","volume":"8","author":[{"given":"Iqbal Ike K.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isra","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-9154","authenticated-orcid":false,"given":"Hady","family":"Saheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Schlenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-9427","authenticated-orcid":false,"given":"Steven","family":"Schendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Muratov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl P.","family":"Ferrufino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-3863","authenticated-orcid":false,"given":"Derek","family":"O'Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2025.01.008_bib1","first-page":"189","article-title":"Minimally invasive glaucoma surgery: current status and future prospects","volume":"10","author":"Richter","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib4","series-title":"Population estimates on July 1st, by age and sex","year":"2022"},{"key":"10.1016\/j.ogla.2025.01.008_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jcjo.2011.06.006","article-title":"The cost of vision loss in Canada. 2. Results","volume":"46","author":"Cruess","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.ophtha.2015.06.022","article-title":"MIGS and the FDA: what's in a Name?","volume":"122","author":"Ahmed","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib19","series-title":"CADTH optimal use reports. Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment","author":"Poitras","year":"2019"},{"key":"10.1016\/j.ogla.2025.01.008_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cts.12660","article-title":"Translating minimally invasive glaucoma surgery devices","volume":"13","author":"Lee","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ogla.2025.01.008_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0974-9233.148347","article-title":"Update on Schlemm's canal based procedures","volume":"22","author":"Mansouri","year":"2015","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ophtha.2022.02.021","article-title":"Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery","volume":"129","author":"Ahmed","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ophtha.2018.05.012","article-title":"A\u00a0Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study","volume":"126","author":"Samuelson","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib28","series-title":"Clinical decisions in glaucoma","author":"Hodapp","year":"1993"},{"key":"10.1016\/j.ogla.2025.01.008_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ajo.2023.02.008","article-title":"Five-year visual field outcomes of the HORIZON trial","volume":"251","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib25","doi-asserted-by":"crossref","first-page":"E733","DOI":"10.1503\/cmaj.181606","article-title":"Embracing the science of value in health","volume":"191","author":"Krahn","year":"2019","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ogla.2025.01.008_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ogla.2019.11.009","article-title":"A\u00a0Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma","volume":"3","author":"Ahmed","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2025.01.008_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ajo.2023.02.008","article-title":"Five-year visual field outcomes of the HORIZON trial","volume":"241","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ogla.2025.01.008_bib31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ophtha.2009.06.063","article-title":"Central and peripheral visual impairment and the risk of falls and falls with injury","volume":"117","author":"Patino","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib60","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1167\/iovs.11-8794","article-title":"Increased mortality risk among the visually impaired: the roles of mental well-being and preventive care practices","volume":"53","author":"Zheng","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2025.01.008_bib61","article-title":"MA3 glaucoma disease progression states: establishing a direct, quantitative link between visual field defects and utility loss","volume":"7","author":"Gerlier","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.ogla.2025.01.008_bib62","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/11316830-000000000-00000","article-title":"Quality of life in glaucoma and three other chronic diseases: a systematic literature review","volume":"26","author":"Mills","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ogla.2025.01.008_bib44","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease","volume":"110","author":"Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5301\/EJO.2010.6112","article-title":"Do adherence rates and glaucomatous visual field progression correlate?","volume":"21","author":"Rossi","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/injuryprev-2019-043184","article-title":"Cataract surgery for falls prevention and improving vision: modelling the health gain, health system costs and cost-effectiveness in a high-income country","volume":"26","author":"Boyd","year":"2020","journal-title":"Inj Prev"},{"key":"10.1016\/j.ogla.2025.01.008_bib32","series-title":"Implantable medical devices in Canada: insights into high-volume procedures and associated costs","year":"2020"},{"key":"10.1016\/j.ogla.2025.01.008_bib33","series-title":"Data on file. Alcon\/IQVIA glaucoma market reserach","year":"2021"},{"key":"10.1016\/j.ogla.2025.01.008_bib34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib35","series-title":"HORIZON clinical study report","year":"2020"},{"key":"10.1016\/j.ogla.2025.01.008_bib37","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0161-6420(98)91133-2","article-title":"The probability of blindness from open-angle glaucoma","volume":"105","author":"Hattenhauer","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ophtha.2011.09.043","article-title":"A\u00a0twenty-year follow-up study of trabeculectomy: risk factors and outcomes","volume":"119","author":"Landers","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib40","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","article-title":"The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity","volume":"118","author":"Sleath","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ophtha.2019.04.034","article-title":"A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study","volume":"127","author":"Ahmed","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.01.008_bib45","series-title":"Data on file, KOL interview","year":"2022"},{"key":"10.1016\/j.ogla.2025.01.008_bib47","series-title":"Ontario drug benefit formualry","year":"2022"},{"key":"10.1016\/j.ogla.2025.01.008_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ogla.2019.11.009","article-title":"A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma","volume":"3","author":"Ahmed","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2025.01.008_bib49","article-title":"Enqu\u00eate sur la population active","year":"2018","journal-title":"adapt\u00e9 par l\u2019Institut de la statistique du Qu\u00e9bec (ISQ)"},{"key":"10.1016\/j.ogla.2025.01.008_bib50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00019053-200523050-00005","article-title":"Valuing patient and caregiver time: a review of the literature","volume":"23","author":"Tranmer","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ogla.2025.01.008_bib51","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2009.96","article-title":"An objective evaluation of eyedrop instillation in patients with glaucoma","volume":"127","author":"Stone","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2025.01.008_bib54","series-title":"Glaucoma management: economic evaluations based on a patient level simulation model","author":"van Gestel","year":"2012"},{"key":"10.1016\/j.ogla.2025.01.008_bib55","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/curroncol29030127","article-title":"Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations","volume":"29","author":"Binder","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ogla.2025.01.008_bib56","first-page":"390","article-title":"Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada","volume":"22","author":"Patel","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ogla.2025.01.008_bib57","author":"Ivantis"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:20:52Z","timestamp":1774272052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419625000274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2589419625000274"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2025.01.008","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Hydrus Microstent for Patients with Mild to Moderate Primary Open-Angle Glaucoma in Canada","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}